No need for clinical trial for redesigned COVID boosters
In this July 1, 2022 article for Reuters, Michael Erman confirms that the US Food and Drug Administration (FDA) will no longer require pharma companies to submit clinical trial data for “updated” COVID shots designed for BA.4 and BA.5 Omicron variants.
Dr. Peter Marks, head of the FDA’s Center for Biologics Evaluation and Research, said that the agency will “rely on data from clinical trials vaccine makers have run on shots designed to combat the BA.1 lineage, as well as manufacturing data, for emergency use authorization submissions before the fall”.
Editor’s Note: We still remember when Dr. Mike Yeadon warned us against this and the rabid attacks he received for voicing out this prediction [see Dr. Mike Yeadon: There is zero chance of new variants escaping immunity].
Now it’s here. Are vaccinated people still “excited” to take this “updated” shot? Or have they finally awakened to the truth that pharma companies are just using them like a milking cow?
Read Original Article
Click the button below if you wish to read the article on the website where it was originally published.
Click the button below if you wish to read the article offline.